Loading clinical trials...
Loading clinical trials...
An Open-label Phase I Dose Finding Trial With BI 891065 Alone and in Combination With BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced and/or Metastatic Malignancies
Conditions
Interventions
BI 891065
BI 754091
Locations
3
United States
Florida Cancer Specialists
Sarasota, Florida, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Start Date
September 8, 2017
Primary Completion Date
September 15, 2020
Completion Date
October 28, 2020
Last Updated
November 19, 2024
NCT03206060
NCT06855771
NCT06608446
NCT07541924
NCT07542041
NCT00033137
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions